NCT00452725View on ClinicalTrials.gov

Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome

PHASE3CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

October 31, 1997

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

Noonan Syndrome

Interventions

DRUG

MAXOMAT ®, biosynthetic growth hormone

2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration

Trial Locations (1)

Unknown

Sanofi-Aventis, Paris

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY